Punnonen R, Liukko P, Cortes-Prieto J, Eydam F, Milojevic S, Trévoux R, Chryssikopoulos E, Franchi F, Luisi M, Kicovic P M
Maturitas. 1984 Apr;5(4):281-6. doi: 10.1016/0378-5122(84)90023-9.
A multicentre study covering 69 post-menopausal or oophorectomized women was performed to determine whether Org OD 14 [7 alpha, 17 alpha)-17-hydroxy-7-methyl-19-norpregn-5(10)-en-20-yn-3-one) administered orally in a daily dose of 2.5 mg for 90 consecutive days induces endometrial proliferation. The treatment with Org OD 14 was continued in combination with 1 mg/day of lynestrenol from day 91 for 10 days to ascertain whether secretory transformation of the endometrium and subsequent withdrawal bleeding would occur. Endometrial biopsies were obtained before treatment and on day 91. The effects of Org OD 14 on vaginal mucosa and cervical mucus were also evaluated. Org OD 14 did not display any effect on the endometrium in 56 of the study subjects (83.5%). Weak stimulation (initial proliferation) was seen in 11 of the subjects (16.4%) and withdrawal bleeding occurred in only 5 of these after cessation of the combined treatment with lynestrenol. However, moderate 'oestrogenic' effects on vaginal mucosa and cervical mucus were induced in all study subjects.
一项涵盖69名绝经后或卵巢切除女性的多中心研究开展,以确定连续90天每日口服2.5毫克Org OD 14([7α, 17α)-17-羟基-7-甲基-19-去甲孕-5(10)-烯-20-炔-3-酮])是否会诱导子宫内膜增生。从第91天起,Org OD 14治疗继续联合1毫克/天的炔雌醇甲醚持续10天,以确定子宫内膜是否会发生分泌期转化及随后的撤退性出血。在治疗前和第91天进行子宫内膜活检。还评估了Org OD 14对阴道黏膜和宫颈黏液的影响。在56名研究对象(83.5%)中,Org OD 14对子宫内膜未显示任何影响。11名研究对象(16.4%)出现轻度刺激(初始增生),在与炔雌醇甲醚联合治疗停止后,其中只有5人发生撤退性出血。然而,所有研究对象的阴道黏膜和宫颈黏液均出现中度“雌激素”效应。